1. Scrip
  2. >>Business
  3. >>Financing

IPO Update: 58 Drug Developers Raised $12.5bn Through Q3

With Three More In Q4, 2020 Total Reaches 61

 
• By Mandy Jackson

The average return for companies that went public in the US through the end of September was 49.4% as of 5 October. The fourth quarter started with three additional initial public offerings on 1 October.

Businessman presses button ipo Initial Public Offering diagram online network. - Image
58 IPOs through Q3 in the US grossed $12.5bn with a 49.4% average return • Source: Shutterstock

The market for biopharmaceutical initial public offerings in the US has grown more impressive in each quarter of 2020 in almost every way. There were nine IPOs in the first quarter, 20 in the second and 29 in the third quarter for a total of 58 first-time offerings by drug developers – eight more than the 50 IPOs for all of 2019. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.

Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings

 
• By Mandy Jackson

There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.

Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives Rise

 
• By Mandy Jackson

Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.